RB1 and neoplasm: These results suggested that GSK503 was an efficient chemical compound to realize the targeted disruption of the CTCF-EZH2 mediating chromatin loop by inhibiting EZH2 activity and thereby to reactivate the RB1 gene in tumor cells without RB1-mutations.